Evidence map›Paper›PMID 27234602›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016

ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers.

Yi-Wei Wang, Xiaotu Ma, Yu-An Zhang, Mei-Jung Wang, Yasushi Yatabe, Stephen Lam, Luc Girard, Jeou-Yuan Chen, Adi F Gazdar

Abstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Wei WangHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas; Institute of Biomedical Sciences, Academia Sinica, Taipei, Republic of China.
Xiaotu MaThe Center for Systems Biology, Department of Molecular and Cell Biology, The University of Texas at Dallas, Richardson, Texas.
Yu-An ZhangHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas.
Mei-Jung WangInstitute of Biomedical Sciences, Academia Sinica, Taipei, Republic of China.
Yasushi YatabeDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Stephen LamBritish Columbia Cancer Research Center, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Luc GirardHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas.
Jeou-Yuan ChenInstitute of Biomedical Sciences, Academia Sinica, Taipei, Republic of China; Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei, Republic of China.
Adi F GazdarHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Pathology and Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: adi.gazdar@utsouthwestern.edu.

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CAU01CA086402 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LEACH, ROBIN JEAN, THOMPSON, IAN M. · 2000 to 2018
$33.1M
Lung cancer oncogenotype-selective drug target discoveryU01CA176284 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MACMILLAN, JOHN B, MINNA, JOHN D. · 2013 to 2016
$2.8M
NCI NIH HHS P50 CA070907NCI NIH HHS U01 CA086402NCI NIH HHS U01 CA176284
6 · The paper itself

Abstract

introductionDespite recent advances in cancer therapy, the overall 5-year survival rate of patients with lung cancer remains low. The aim of our study was to search for novel markers for early diagnosis in patients with lung cancer.

methodsComplementary DNA microarray analysis was performed in primary lung adenocarcinomas and cell lines to search for differentially expressed genes, followed by in vivo and in vitro tumorigenic assays to characterize the oncogenic potential of the candidate genes. Gene body methylation was analyzed by 450K methylation array, bisulfite sequencing, and quantitative methylation-specific polymerase chain reaction assays. In silico analysis of The Cancer Genome Atlas data set was also performed.

resultsInositol-trisphosphate 3-kinase A gene (ITPKA), a kinase with limited tissue distribution, was identified as a potential oncogene. We showed that ITPKA expression is up-regulated in many forms of cancers, including lung and breast cancers, and that overexpressed ITPKA contributes to tumorigenesis. We also demonstrated that ITPKA expression is regulated by epigenetic DNA methylation of ITPKA gene body through modulation of the binding of SP1 transcription factor to the ITPKA promoter. ITPKA gene body displayed low or absent levels of methylation in most normal tissue but was significantly methylated in malignant tumors. In lung cancer, ITPKA gene body methylation first appeared at the in situ carcinoma stage and progressively increased after invasion.

conclusionsITPKA is a potential oncogene that it is overexpressed in most tumors, and its overexpression promotes tumorigenesis. ITPKA gene body methylation regulates its expression and thus serves as a novel and potential biomarker for early cancer detection.

Indexed as

DNA MethylationEarly Detection of CancerGene Expression Regulation, NeoplasticBiomarkers, TumorCell Line, TumorHumansLung NeoplasmsPhosphotransferases (Alcohol Group Acceptor)Biomarkers, TumorInositol 1,4,5-trisphosphate 3-kinasePhosphotransferases (Alcohol Group Acceptor)BiomarkerGene body methylationITPKAOncogeneSP1

Identifiers

PMID27234602
PMCPMC5555593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.